Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

Abstract

Thalidomide plus interferon maintenance therapy increased progression-free survival but not overall survival and was associated with slightly more toxicity than maintenance with interferon alone. (ClinicalTrials.gov Identifier: NCT00205751).